ClinicalTrials.gg
RecruitingNCT06182059Updated Sep 21, 2026

Persistent Post Surgical Pain After Total Knee Arthroplasty

An interventional study of continuous peripheral nerve block in Knee Arthropathy, sponsored by Policlinico di Monza SpA. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Policlinico di Monza SpA · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
436
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 115 studies in Pain, Postoperative with a site in Italy — 17 open to participants now, 20 under way, none of them phase 3. Pain, Postoperative · Italy.

Planned enrollment
4th of 86
436 · median 79
Started
2024
with 4 others
No phase
63 of 115
11 open now
Primary completion
2027-01
later than 13 of 19 live
Registered
94th of 115
by date

Among the 115 studies in Pain, Postoperative with a site in Italy, this one is the 4th largest by planned enrollment of the 86 interventional ones that give a count, is one of 5 that started in 2024, is one of 63 with no phase, reaches primary completion later than 13 of the 19 other live ones, and was the 94th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

17 of the 115 studies in Pain, Postoperative with a site in Italy are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Pain, Postoperative with a site in Italy, or all of them as a file.
02

Study summary

Patients undergone total knee replacement are randomized to receive a "fast track" regional anesthesia protocol or a "traditional" regional anesthesia continuous infusion by both a femoral and sciatic catheter to assess if this latter technique may reduce persistent postoperative pain six months after surgery

Read the detailed description

Patients undergone to primary total knee replacement with spinal anesthesia are randomized to receive a continuous adductor canal block infusion + an ipack block or a continuous femoral nerve block + a continuous sciatic nerve block just at the end of surgery. Both group will receive a multimodal analgesia with paracetamol, ketorolac, desametasone and morphine as a rescue.

03

Conditions studied

  • Knee Arthropathy

Browse trials for

Keywords

  • knee arthroplasty
  • acute postoperative pain
  • persistent post surgical pain
  • regional anesthesia
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • primary total knee replacement with a written

Exclusion criteria

Exclusion Criteria:

  • Allergy to local anesthetics or any drugs involve in the study
  • Controindication to regional anesthesia
  • chronic use of opioids
  • > 35 kg m2
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
436 participants (estimated)

Study arms

  • Active comparator
    fast track

    continuous adductor canal block and ipack block

    Procedure: continuous peripheral nerve block

  • Experimental
    traditional

    continuous femoral nerve block and continuous sciatic block

    Procedure: continuous peripheral nerve block

Interventions

  • Procedurecontinuous peripheral nerve block

    continuous regional anesthesia in total knee replacement

06

What researchers measure

Primary outcomes

  1. Persistent post surgical pain

    Numeric rating score (0-10) over 4 at the follow up 6-month after total knee replacement

    Time frame: 0-6-month

Secondary outcomes

  1. acute postoperative pain

    Numeric rating score (0-10) over 4 in POD0, POD1, POD2, POD3

    Time frame: 0-72 hours

  2. Morphine requirement

    total morphine administration via PCA in POD0, POD1, POD2, POD3

    Time frame: 0-72 hours

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2027, 36 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 36 months is above that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2023
First posted
Dec 26, 2023
StartActual
Jan 12, 2024
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06182059
Lead sponsor
Policlinico di Monza SpA
Responsible party
Gianluca Cappelleri (MD, Policlinico di Monza SpA) — Principal investigator
First posted
Dec 26, 2023
Start date
Jan 12, 2024
Primary completion
Jan 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Sep 21, 2026

Study contacts

Gianluca Cappelleri, MD
Contact
gianluca.cappelleri@policlinicodimonza.it
+390392810941
Gianluca Perseghin, MD
Contact
gianluca.perseghin@policlinicodimonza.it
+3903928109

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion